Hodgkin’s lymphoma stage I/II Untreated, age 15-70 Favorable CS I and II (max. 3 nodal areas) and <50years and MT ratio<0.35 and ESR<50 (no B symptoms) or ESR<30 (B symptoms present) Unfavorable CS II (≥ 4 nodal areas) or ≥50years or MT ratio≥0.35 or ESR≥50 (without B symptoms) Randomization Randomization Standard (Any outcome of PET scan) Experimental (According to PET scan) Standard (Any outcome of PET scan) Experimental (According to PET scan) 2 cycles ABVD + FDG-PET (2nd period) PET negative PET positive PET negative PET positive 1 cycle ABVD + IN-RT 30Gy 2 cycles ABVD 2 cycles escalated BEACOPP + IN-RT 30Gy 2 cycles ABVD + IN-RT 30Gy 4 cycles ABVD 2 cycles escalated BEACOPP + IN-RT 30Gy After amendment in 2010: 1 cycle ABVD + IN-RT 30Gy 1 cycle ABVD + IN-RT 30Gy 2 cycles escalated BEACOPP + IN-RT 30Gy 2 cycles ABVD + IN-RT 30Gy 2 cycles ABVD + IN-RT 30Gy 2 cycles escalated BEACOPP + IN-RT 30Gy